CD274 and hyperthyroidism: Durvalumab (Imfinzi®) is a PD-L1 inhibitor belonging to the IgG1 subclass, approved by the FDA in 2017 for the treatment of urothelial carcinoma and NSCLC (13, 82), while inducing hypothyroidism and hyperthyroidism as irAEs (64).